Clinical Trial

Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated July 22, 2024 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
It is a single-center, single-arm, open-labeled clinical trial to evaluate the efficacy and safety of CAR-T cells therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-02.
Trial Details
NCT Number NCT06352281
Lead Sponsor 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Conditions ITP - Immune Thrombocytopenia
Enrollment 10 participants
Start Date 2024-02-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-22